Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic

Journal of Psychopharmacology

Volumn 27, Issue 2, 2013, Pages 135-145

  Diaper, Alison ^a   Osman Hicks, Victoria ^a   Rich, Ann S ^a   Craig, Kevin ^b   Dourish, Colin T ^b   Dawson, Gerard R ^b   Nutt, David J ^c   Bailey, Jayne E ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anxiety; carbon dioxide; experimental human model; panic; pregabalin; venlafaxine

Indexed keywords

CARBON DIOXIDE; PLACEBO; PREGABALIN; VENLAFAXINE;

ADULT; ARTICLE; CARBON DIOXIDE BREATHING; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; EVENING DOSAGE; FATIGUE; FEMALE; GABAERGIC SYSTEM; GENERALIZED ANXIETY DISORDER; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INSOMNIA; MALE; MORNING DOSAGE; NORMAL HUMAN; PANIC; PARALLEL DESIGN; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; SINGLE BLIND PROCEDURE; TRANQUILIZING ACTIVITY; VITAL CAPACITY; VOLUNTEER;

ADMINISTRATION, INHALATION; ADULT; ANXIETY DISORDERS; BLOOD PRESSURE; CARBON DIOXIDE; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEART RATE; HUMANS; MALE; PANIC; QUESTIONNAIRES; YOUNG ADULT;

EID: 84868558719     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112443742     Document Type: Article

References (57)

1. Argyropoulos SV, Bailey JE, Hood SO, et al. Inhalation of 35% CO2 results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology. 2002 ; 27: 715-729
2. Attwood AS, Saeed F, Bailey J, et al. Effects of carbon dioxide challenge on anxiety in cigarette smokers. Paper presented at the Society for Research on Nicotine and Tobacco, Dublin ; ;..
3. Bailey JE, Argyropoulos SV, Lightman SL, Nutt DJ. Does the brain noradrenaline network mediate the effects of the CO2 challenge?. ; 2003 ; 2003. 252.
4. Bailey JE, Nutt DJ J Psychopharmacol. A ; 2001: K1.
5. Bailey JE, Nutt DJ. Are personality factors related to the CO2 response in healthy volunteers?. J Psychopharmacol. 2005 ; 19: A18
6. Bailey JE, Nutt DJ. GABA-A receptors and the response to CO2 inhalation - a translational trans-species model of anxiety?. Pharmacol Biochem Behav. 2008 ; 90: 51-57
7. Bailey JE, Argyropoulos SV, Kendrick A, et al. Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depress Anxiety. 2005 ; 21: 18-25
8. Bailey JE, Kendrick A, Diaper A, et al. A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. J Psychopharmacol. 2007 ; 21: 42-49
9. Bailey JE, Papadopoulos A, Seddon K, et al. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety. J Psychopharmacol. 2009 ; 23: 117-122
10. Bailey JE, Papadopoulos A, Diaper A, et al. Preliminary evidence of anxiolytic efficacy of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety. J Psychopharmacol. 2011 ; 25 (9). 1199-1206
11. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 ; 19: 567-596
12. Bandelow B, Wedekind D, Leon T.. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Exp Rev Neurother. 2007 ; 7: 769-781
13. Bell C, Forshall S, Adrover M, et al. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol. 2002 ; 16: 5-14
14. Bertani A, Perna G, Arancio C, et al. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a doubleblind, random, placebo-controlled study. J Clin Pharmacol. 1997 ; 17: 97-101
15. Bertani A, Caldirola D, Bussi R, et al. The 35% CO2 hyperreactivity and clinical symptomology in patients with panic disorder after 1 week of treatment with citalopram: an open study. J Clin Psychopharmacol. 2001 ; 21: 262-267
16. Clark OM, Hemsley DR. The effects of hyperventilation; individual variability and its relation to personality. J Behav Ther Exp Psychiatry. 1982 ; 13: 41-47
17. Cloninger CR, Przybeck TR, Svrakic DM. The tridimensional personality questionnaire: U.S. normative data. Psychol Rep. 1991 ; 69: 1047-1057
18. Cloninger CR, Pryzbeck TR, Svrakic DM, Wetzel RD St. Louis, MO: Center for Psychobiology of Personality, Washington University ; 1994 :
19. Coupland NJ, Bailey JE, Wilson SJ, et al. The effects of clonidine on cardiovascular responses to standing in healthy volunteers. Clin Autonom Res. 1995 ; 5: 171-177
20. Davidson JRT, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999 ; 60: 528-535
21. Davidson JRT, Feltner DE, Dugar A. Management of Generalized Anxiety Disorder in primary care: identifying the challenges and unmet needs. J Clin Psychiatry. 2010 ; 12: e1 - e13
22. Eysenck HJ, Eysenck SBG Manual of the Eysenck Personality Scales (EPS Adult). London: Hodder and Stoughton ; 1991 :
23. Eysenck SBG, Eysenck HJ, Barrett P. A revised version of the psychoticism scale. Person Indiv Diff. 1985 ; 6: 21-29
24. File SE, Lister RG. A comparison of the effects of lorazepam with those of propranolol on experimentally-induced anxiety and performance. Br J Clin Pharmacol. 1985 ; 19: 445-451
25. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996 ; 271: 5768-5776
26. Gorman JM, Browne ST, Papp LA, et al. Effect of antipanic treatment on response to carbon dioxide. Biol Psychiatry. 1997 ; 42: 982-991
27. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995 ; 49: 280-294
28. Hood SD, Melichar JK, Taylor LG, et al. Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. J Psychopharmacol. 2010 ; 25: 78-86
29. Kelsey JE. Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder. Depress Anxiety. 2000 ; 12: 81-84
30. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 ; 62: 593-602
31. Kim TS, Pae CU, Yoon SJ, et al. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2006 ; 60: 347-351
32. Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005 ; 66: 238-247
33. Liebowitz MR, Asnis G, Mangano R, et al. A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry. 2009 ; 70: 550-561
34. Lydiard RB, Rickels K, Herman B, et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010 ; 13: 229-241
35. Meoni P, Hackett D, Lader M. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder. Depress Anxiety. 2004 ; 19: 127-132
36. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006 ; 67: 771-782
37. Nardi AE, Valenca AM, Nascimento I, et al. Double-blind acute clonazepam vs. placebo in carbon dioxide-induced panic attacks. Psychiatry Res. 2000 ; 94: 179-184
38. Nutt DJ, Glue P, Lawson C, et al. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry. 1990 ; 47: 917-925
39. Papadopoulos A, Rich A, Nutt DJ, et al. The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures. J Psychopharmacol. 2010 ; 24: 649-656
40. Perna G, Bertani A, Gabriele A, et al. Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomised, placebo-controlled study. J Clin Psychopharmacol. 1997 ; 17: 173-178
41. Peterson RA, Reiss RJ 1992 ) Anxiety Sensitivity Index Manual (2nd ed.). Worthington, OH: International Diagnostic Systems. Worthington, OH: International Diagnostic Systems ; 1992 :
42. Pohl RB, Feltner DE, Fieve RR, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005 ; 25: 151-158
43. Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007 ; 24: 1-14
44. Pols HJ, Hauzer RC, Meijer JA, et al. Fluvoxamine attenuates panic induced by 35% CO2 challenge. J Clin Psychiatry. 1996 ; 57: 539-542
45. Reiss S, McNally RJ Theoretical Issues in Behavior Therapy. Reiss S Bootzin RR, ed. New York: Academic Press ; 1985 :
46. Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry. 1988 ; 45: 444-450
47. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993 ; 50: 884-895
48. Sanderson WC, Wetzler S, Asnis GM. Alprazolam blockade of CO2-provoked panic in patients with panic disorder. Am J Psychiatry. 1994 ; 151: 1220-1222
49. Schruers K, Griez E. The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. J Psychopharmacol. 2004 ; 18: 553-558
50. Seddon KM, Morris K, Bailey J, et al. Effects of 7.5% CO2 challenge in generalized anxiety disorder. J Psychopharmacol. 2010 ; 25: 43-51
51. Spielberger CD Manual for the State-Trait Anxiety Inventory (Form Y). California, USA: Consulting Psychologists Press, Inc ; 1983 :
52. Stahl SM, Ahmed S, Haudiquet V. Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. CNS Spectr. 2007 ; 12: 703-711
53. Tiihonen J, Kuikka J, Rasanen P, et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: A fractal analysis. Mol Psychiatry. 1997 ;: 463-471
54. Valença A, Nardi AE, Nascimento I, et al. Acute clonazepam dose in carbon dioxide induced panic attacks. CINP Meeting, abstract no. P. 09. 2000 ; 056: S284
55. Valença AM, Nardi AE, Nascimento I, et al Arq Neuropsiquiatr. 60-B: ; 2002: 358-361.
56. Ying DG, Jiang S, Yang H, et al. Frequency of generalized anxiety disorder in Chinese primary care. Postgrad Med. 2010 ; 122: 32-38
57. Zwanzger P, Eser D, Aicher S, et al. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal- axis activity: a placebo-controlled study. Neuropsychopharmacology. 2003 ; 28: 979-984